{"id":9049,"date":"2022-09-16T14:49:00","date_gmt":"2022-09-16T12:49:00","guid":{"rendered":"https:\/\/czecrin.cz\/project\/kh-m-a-r-s\/"},"modified":"2026-01-27T13:58:28","modified_gmt":"2026-01-27T12:58:28","slug":"kh-m-a-r-s","status":"publish","type":"project","link":"https:\/\/czecrin.cz\/en\/project\/kh-m-a-r-s\/","title":{"rendered":"CT M.A.R.S."},"content":{"rendered":"\n

CLINICAL TRIAL M.A.R.S.<\/h3>\n\n\n\n
\n\n\n\n
<\/div>\n\n\n\n

M.A.R.S. is a randomised double-blind placebo-controlled multicentre study of the efficacy and safety of highly diluted atropine collyrium in retarding the development of myopia in children, a phase IIIb study with three parallel arms designed to increase clinical knowledge of the effect of topical application of highly diluted atropine on axial length growth in myopic eyes and to add to experimental knowledge of the efficacy and safety of this application.<\/p>\n\n\n\n

The study was initiated by the University Hospital Brno in cooperation with Masaryk University. It is a paediatric clinical trial that will enrol a total of 236 patients in 5 centres in the Czech Republic.<\/p>\n\n\n\n

OVERVIEW OF RECRUITMENT<\/h6>\n\n\n\n

Patient recruitment<\/strong> started on 29 June 2022<\/strong> and was completed on 29 August 2024<\/strong>. A total of 236 patients<\/strong> were enrolled in the study.<\/p>\n\n\n\n

Total number of enrolled patients:<\/strong> 236\/236<\/p>\n\n\n\n

Important links to the project<\/h2>\n\n\n\n
\n\n\n\n
<\/div>\n\n\n\n
Access to the REDCap database (for examiners)<\/a><\/strong><\/td>Clinical Trials register – Search for 2020-002046-16<\/a><\/strong><\/td>Official project website<\/a><\/strong><\/td><\/tr>
Publications<\/a><\/strong><\/td>Document: Transfer of the Clinical Trial to the CTIS portal as of 01 November 2024<\/a><\/strong><\/td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
<\/div>\n\n\n\n

Trial documents<\/h2>\n\n\n\n
\n\n\n\n
<\/div>\n\n\n\n
Approval of S\u00daKL<\/a><\/strong><\/td>Approval of MEK FN Brno<\/a><\/strong><\/td>The Rationale of clinical trial<\/a><\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
<\/div>\n\n\n\n
<\/div>\n\n\n\n
Contact<\/h5>\n\n\n\n

Study sponsor:
FN Brno | prof. MUDr. Rudolf Autrata, CSc., MBA | autrata.rudolf@fnbrno.cz<\/a><\/p>\n\n\n\n

<\/div>\n\n\n\n

Project manager:
Mgr. et Bc. \u0160\u00e1rka Maty\u0161kov\u00e1 | matyskova@med.muni.cz<\/a> <\/p>\n\n\n\n

<\/div>\n\n\n\n